Cytomx Therapeutics Stock Widgets and Gadgets
CTMX Stock | USD 2.18 0.01 0.46% |
Intraday Equity Chart Quick Equity Feed Equity Search Quote Ticker Widgets Data Sheet |
Live Stock Ticker Example
- CTMX CytomX Therapeutics
- Latest Q1 2024 Earnings Forecast for CytomX Therapeutics, Inc. Issued By HC Wainwright - MarketBeat
- CTMX 2.18 -0.01
- Low 2.17
- High 2.3
- Volume 2.9 M
- Alpha 0.51
- Beta 2.21
- Return On Equity -54.75
- Return On Asset -0.0175
- Profit Margin (0.01) %
- Operating Margin (0.02) %
- Current Valuation (11.55 M)
- Shares Outstanding 67.72 M
- Shares Owned By Insiders 1.33 %
- Shares Owned By Institutions 48.63 %
- Number Of Shares Shorted 3.53 M
- Price To Earning (11.41) X
- Price To Book 5.04 X
- Price To Sales 1.47 X
- Revenue 101.21 M
- Gross Profit 53.16 M
- EBITDA (4.31 M)
- Net Income (569 K)
- Cash And Equivalents 194.29 M
- Cash Per Share 2.94 X
- Total Debt 13.97 M
- Debt To Equity 0.67 %
- Current Ratio 2.05 X
- Book Value Per Share (0.70) X
- Cash Flow From Operations (56.03 M)
- Short Ratio 1.97 X
- Earnings Per Share (0.01) X
- Price To Earnings To Growth (1.80) X
- Target Price 2.9
- Number Of Employees 120
- Beta 1.01
- Market Capitalization 148.99 M
- Total Asset 205.15 M
- Retained Earnings (723.45 M)
- Working Capital 27.02 M
- Current Asset 189.75 M
- Current Liabilities 15.74 M
- Z Score 2.04
- Net Asset 205.15 M
- Accumulation Distribution 161370.0
- Daily Balance Of Power (0.08)
- Rate Of Daily Change 1.0
- Day Median Price 2.24
- Day Typical Price 2.22
- Price Action Indicator (0.06)
- Period Momentum Indicator (0.01)
Market Snapshot Widget Example
DAX Index Germany | 18,492 0.08 | |
Taiwan Weighted Taiwan | 20,147 0.27 | |
PSI 20 Stock Portugal | 6,280 0.06 | |
CROBEX Croatia | 2,835 0.28 | |
Budapest SE Hungary | 65,385 0.86 | |
IDX 30 Jakarta Indonesia | 501.16 0.43 | |
ISEQ 20 Price Ireland | 1,637 0.3 | |
NYSE Comp USA | 18,313 0.31 | |
Tel Aviv 35 Israel | 2,009 0.52 | |
Coreshares Index Tracker South Afric | 1,052 0.57 | |
IPC MEXICO Mexico | 57,369 0.28 | |
KL Technology Malaysia | 64.31 0.42 | |
IBEX 35 Index Spain | 11,075 0.33 | |
SP Merval Argentina | 1,000,000 0.00 | |
Austrian Traded Index Austria | 3,536 0.35 | |
SPASX Dividend Opportunities Australia | 1,686 1.06 | |
HNX 30 Vietnam | 535.69 0.53 | |
Bucharest BET-NG Romania | 1,210 0.34 | |
AMS Small Cap Netherlands | 1,223 0.45 | |
Oslo Exchange Mutual Norway | 1,280 0.47 | |
BEL Small Belgium | 9,273 0.52 | |
RTSI Index Russia | 1,126 0.19 | |
Basic Materials Brazil | 6,016 0.18 | |
Swiss Leader Price Switzerland | 1,924 0.25 | |
Athens General Comp Greece | 1,422 0.34 | |
Stock Exchange Of Thailand | 1,370 0.76 | |
PX Prague Stock Czech Repub | 1,513 1.55 | |
THE PHILIPPINE STOCK Philippines | 6,904 0.08 | |
WIG 30 Poland | 3,022 1.59 | |
BIST Electricity Turkey | 544.86 1.57 |
Investing Ideas
In addition to having CytomX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Thematic Opportunities
Explore Investment Opportunities
Compare CytomX Therapeutics
Compare CytomX Therapeutics To Peers
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.